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Abstract
We performed a service-based epidemiological study of
dystonia in Munich, Germany. Due to favourable referral
and treatment patterns in the Munich area, we could pro-
vide confident data from dystonia patients seeking botu-
linum toxin treatment. A total of 230 patients were ascer-
tained, of whom 188 had primary dystonia. Point preva-
lence ratios were estimated to be 10.1 (95% confidence
interval 8.4–11.9) per 100,000 for focal and 0.3 (0.0–0.6)
for generalised primary dystonia. The most common
focal primary dystonias were cervical dystonia with 5.4
(4.2–6.7) and essential blepharospasm with 3.1 (2.1–4.1)
per 100,000 followed by laryngeal dystonia (spasmodic
dysphonia) with 1.0 (0.4–1.5) per 100,000.
Copyright © 2002 S. Karger AG, Basel
Introduction
Dystonia is defined as a syndrome of sustained invol-
untary muscle contractions, frequently causing twisting,
repetitive movements or abnormal postures [1]. It can
affect virtually any part of the body and is classified
accordingly. It is also classified by etiology as follows: pri-
mary dystonia, where the phenotype is of dystonia alone
with the exception that tremor can be present as well; dys-
tonia-plus syndromes, where the clinical phenotypes in-
clude other neurologic features in addition to dystonia (at
present there are two such dystonia-plus conditions:
dopa-responsive dystonia and dystonia-myoclonus); sec-
ondary dystonia, resulting from environmental factors
(e.g. drugs, stroke, cerebral palsy, tumors), and finally her-
edodegenerative diseases, which present as a dystonia-
plus syndrome with underlying neurodegeneration (e.g.
Wilson’s disease, Huntington’s disease, X-linked dystonia
parkinsonism) [1].
Historically, dystonia has been considered to be a rare
disorder. The advent of an effective treatment by weak-
ening dystonic muscles with localised injections of botu-
linum toxin increased clinical interest in the disease and
hence recognition. Due to the high costs associated with
this therapy, dystonia has become a disease with econom-
ic implications in terms of public health [2]. Therefore,
epidemiological data can provide important information
for cost analysis as well as for the planning of appropriate
patient care. However, few epidemiologic studies have
been carried out [3–8] (table 1), none so far in Germany.
We present service-based data on the point prevalence of
dystonia in Munich, Germany, that were collected during
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Table 1. Prevalence ratios per 100,000 from previous studies of dystonia including focal dystonias
Location and year of publication Type of dystonia
generalised focal blepharospasm cervical writer’s cramp laryngeal
Rochester, USA, 1988 [3] 3.4 (0.4–12.4) 29.5 (17.2–47.9) 1.7 (0.1–9.6) 8.9 (2.9–20.7) 6.9 (1.9–17.6) 5.2 (1.1–15.1)
Tottori, Japan, 1995 [11] – 6.1 (3.1–9.2) 1.61 (0.1–3.2) 2.9 (0.8–4.9) 1.6 (0.1–3.2) –
SW Finland, 1996 [6] – – – 20.9 (16.8–25.6) – –
Northern England, 1998 [5] 1.4 (1.0–1.9) 12.9 (11.5–14.3) 3.0 (2.4–3.7) 6.1 (5.2–7.1) 0.7 (0.4–1.1) 0.8 (0.5–1.3)
ESDE, 2000 [8] – 11.7 (10.8–12.6) 3.6 (3.1–4.1) 5.7 (5.1–6.4) 1.4 (1.1–1.7) 0.7 (0.5–0.9)
1 Ratio includes both oromandibular and blepharospasm combined.
Methods
The catchment area for this cross-sectional study was the city lim-
its of Munich. Included were individuals with at least a 3-month his-
tory compatible with dystonia-plus signs of dystonia at examination,
as defined by Fahn [9], during the period of the study (January–
December 1996), and residing in the catchment area at the designat-
ed prevalence date (June 1, 1996). In Munich, services that provide
botulinum toxin treatment are concentrated in the movement disor-
der clinics of the two universities to which most patients are referred.
The two local neurologists and one otolaryngologist-phoniatrician
known to carry out treatment with botulinum toxin were asked to
participate in this study and provided anonymous information about
their patients with dystonia. In Germany, botulinum toxin treatment
for dystonia is covered by the health insurances (public and private
health insurances) and the social welfare in the rare case of a patient
lacking insurance coverage.
Patients who visited the dystonia and botulinum toxin clinics
during the period of the study were examined and ascertained,
whether this was their first visit or not. In addition, medical records
of patients diagnosed with any type of dystonia between 1989 and
1995 were reviewed. Patients identified by these means were con-
tacted and interviewed in order to verify their current clinical and
demographic situation.
For each diagnosed case of dystonia, an anonymous data collec-
tion sheet was completed. Information was collected on the patients’
age and sex, as well as on the type of dystonia. Dystonia was divided
into primary dystonia with the following subgroups: dopa-responsive
dystonia, paroxysmal kinesigenic dystonia, paroxysmal dystonic
choreoathetosis and myoclonic dystonia. For secondary dystonia, the
specific cause was recorded using the following categories: tardive
dystonia (meaning exposure to neuroleptic or other dopamine recep-
tor-blocking agents for at least 3 months and onset of dystonia within
6 months after discontinuing the drug), cerebrovascular disease, cere-
bral palsy, cerebral neoplasm, cerebral trauma, Wilson’s disease and
other causes. The distribution of dystonia was recorded by location.
In addition, the year of onset was also recorded to calculate the age at
onset.
All data sheets were entered on Microsoft Excel. Means and stan-
dard deviations were calculated by standard methods. Comparisons
of normally distributed continuous variables were performed using
Student’s t test. For the calculations of sex ratios, we used the one-
sample binomial test. Significance testing for differences between
proportions was calculated using the ¯2 test. All p values are two-
sided and at the 5% level.
For calculating the point prevalence ratio, the denominator was
the entire Munich population. We used the mean of the calculated
prevalence for December 1995 and December 1996 (1,322,883).
These values were provided by the Department of Statistics of
Munich. Confidence intervals were calculated using the Poisson dis-
tribution.
Results
A total of 230 prevalent cases were identified. Two
hundred and nine (90.9%) were seen in one of the univer-
sity movement disorder clinics, 89% of them (186 cases)
were ascertained during the year 1996 as they visited one
of the university clinics and 11% (23 cases) were acquired
by review of medical records. Twenty-one patients (9.1%)
came from other clinics or practice.
One hundred and eighty-eight cases (81.7%) had pri-
mary and 42 (18.3%) secondary dystonia. No cases of
dopa-responsive, paroxysmal kinesigenic dystonia, parox-
ysmal dystonic choreoathetosis or myoclonic dystonia
were found.
Among the secondary dystonias, 34 cases (81.7%) were
induced by neuroleptics. Two patients had generalised
dystonia due to perinatal damage, 4 developed dystonia
after a stroke (2 of them had focal and 2 hemidystonia), 1
showed segmental brachial dystonia in a context of corti-
cal-basal ganglionic degeneration and 1 developed focal
upper limb dystonia probably due to a local trauma.
The prevalence and sex ratios of primary dystonia sub-
types are shown in table 2. Cervical dystonia was the most
common focal primary dystonia, representing more than
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Table 2. The prevalence of primary






Blepharospasm 41 (21.8) 3.1 2.1–4.1 1:2.24
Cervical 72 (38.3) 5.4 4.2–6.7 1:1.34
Laryngeal 13 (6.9) 1.0 0.4–1.5 1:1.34
Other focal forms1 8 (4.3) 0.6 0.2–1.0 1:1.04
Segmental 39 (20.7) 3.0 2.0–3.9 1:2.34
Multifocal 11 (5.9) 0.8 0.3–1.3 1:0.84
Generalised 4 (2.1) 0.3 0.0–0.6 1:1.04
1 Writer’s cramp: 3 males; oromandibular dystonia: 1 female and 1 male; pharyngeal dysto-
nia: 1 female; focal limb dystonia: 2 females.
2 Percentages are shown in parentheses.
3 Crude prevalence ratio per 100,000.
4 Not statistically significant (¯2 and binomial test).
Table 3. Age of onset for primary dystonia







SD = Standard deviation.
spasm. It is also noted that laryngeal dystonia was about 5
times more prevalent than writer’s cramp. The total prev-
alence of dystonia was 17.4 per 100,000 [95% confidence
interval (CI) 15.1–19.7], for primary dystonia 14.2 (95%
CI 12.2–16.3), for secondary dystonia 3.2 (95% CI 2.2–
4.1) and for tardive dystonia 2.6 (95% CI 1.7–3.4). In the
group of primary dystonias, the prevalence of all focal
dystonias was 10.1 per 100,000 (95% CI 8.4–11.9), more
than 30 times that of generalised dystonia (0.3, 95% CI
0.0–0.6). Table 3 shows the mean age of onset for differ-
ent types of primary dystonia. As expected, more severe
dystonias showed a younger age of onset. We observed a
significantly earlier age of onset in males as opposed to
females for blepharospasm (51.8 versus 59.6) (p = 0.04).
For the other forms of primary dystonia, there was no sig-
nificant sex difference.
Discussion
To our knowledge, this study is the first to document
the prevalence of dystonia in Germany. The cases have all
been diagnosed by experts in the field of movement disor-
ders, using internationally recognised, standardised diag-
nostic criteria. As part of the Epidemiological Study of
Dystonia in Europe (ESDE) Collaborative Group [7, 8],
the Munich area has the advantage of active collaboration
between the centres providing botulinum toxin treatment.
Therefore, due to these favourable referral and treatment
patterns, we could provide reliable data from patients
treated with botulinum toxin. The results presented here
may have implications regarding botulinum toxin clinic
service provision [2].
In addition, we evaluate the prevalence of secondary
dystonia. Although it is probably underreported here, the
figures may provide some idea about this generally un-
known prevalence.
Our figures for primary dystonia are similar to those
from the ESDE Collaborative Group [8]. This study pro-
vides prevalence data for primary dystonia across eight
European countries (table 1).
The present study has obviously the methodological
limitations of a referral-based survey, as just the diag-
nosed and referred cases could be ascertained. Patients
were mostly referred for botulinum toxin treatment. This
may have led to an increased proportion of focal and seg-
mental dystonias and at the same time to the underreport-
ing of generalised and multifocal dystonias, since these
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those with focal dystonia. Likewise, most patients with
generalised dystonia have childhood onset. Pediatric pa-
tients were only rarely referred to adult neurological prac-
tices for botulinum toxin which at the time of the study
was not used by neuropediatricians. These problems may
also explain why we did not ascertain any case of dopa-
responsive dystonia. However, the clinical presentation of
dopa-responsive dystonia is very variable and often mis-
diagnosed [10].
The prevalence rates of primary dystonia are lower
than those reported by Nutt et al. [3], which were based on
the records of the Mayo Clinic, Rochester, Minn., USA,
but similar to those by Duffey et al. [5], except for general-
ised dystonia (table 1). Duffey et al. [5] performed a com-
munity-based study in the northeast of England that
included a number of complementary methods, such as
an awareness-raising campaign, recruitment of patients
from dystonia self-help groups, as well as a postal survey
in a restricted area.
Compared with our data, Nakashima et al. [11] re-
ported a lower prevalence of focal dystonias in the west-
ern part of Tottori Prefecture in Japan. These authors sug-
gested that genetic factors may account for the low preva-
lence compared with the study of Nutt et al. [3]. In con-
trast, the prevalence ratio for cervical dystonia in south-
western Finland reported by Erjanti et al. [6] was more
than twice as high as the ratio observed in our study and
in Rochester.
The true prevalence of dystonia is difficult to estimate.
There are several reasons for this: as family studies have
shown [12, 13], dystonia is underreported, since many
patients with mild symptoms are not aware of their condi-
tion. Dystonia is also frequently undiagnosed. In their
series, Butler et al. [14] reported that a total of 66.7% of
patients needed at least five consultations before diagno-
sis was achieved and 65.7% were misdiagnosed at some
stage. Finally, as all studies looking at the prevalence of
focal dystonias are service-based rather than community-
based, except the study by Duffey et al. [5], the compara-
bility of the centre estimates is problematic. The differ-
ences in ratios could be explained by ascertainment and
selection bias, but may also reflect an underlying environ-
mental or genetic factor. We identified 42 patients with
secondary dystonia. We have probably missed the cases
due to metabolic or structural disorders present in child-
hood. Nevertheless, our proportions are strikingly similar
to those reported by Fahn et al. [15]. In their series, sec-
ondary dystonia represented 23% of all the cases: 12% of
focal dystonia, 14% of segmental, 46% of multifocal and
42% of generalised dystonia. In our series, 18.3% of the
cases are secondary dystonia, accounting for 7% of focal
dystonia, 35% of segmental, 38% of multifocal and 33%
of generalised dystonia.
The most common cause of secondary dystonia in the
present study was exposure to neuroleptics in 34 cases,
yielding a prevalence ratio of 2.6 per 100,000. The given
prevalence of tardive dystonia in the neuroleptic-treated
population ranges from 0.4 to 21% [16]. However, it is
likely that many of the tardive dystonia patients are not
referred to neurology clinics, as the prevalence is so high
in long-term psychiatric institutions. In agreement with
other reports [3, 5, 8, 17], the most common type of focal
dystonia was cervical dystonia, followed by blepharo-
spasm with prevalence ratios of 5.4 and 3.1 per 100,000,
respectively. However, our estimate for writer’s cramp
differs from the series of Nutt et al. [3], Soland et al. [17],
Duffey et al. [5] and the ESDE Collaborative Group [8]
where writer’s cramp accounted for 21, 19, 6 and 12% of
focal dystonias, respectively. We found that writer’s
cramp just accounted for 2.2% of our focal dystonia
patients, yielding a prevalence of 0.2 per 100,000 (95% CI
0.0–0.5). Nevertheless, taking the CIs into account, our
figures are again comparable with those from Duffey et al.
[5] (0.7 per 100,000, 95% CI 0.4–1.1).
Comparing the mean age of onset in men and women,
we found a significantly earlier age in males for blepharo-
spasm (51.8 versus 59.6). Sex differences depending on
the age of onset have also been recently reported in the
ESDE study [7] for primary focal and segmental dystonia.
This study observed a significantly earlier age of onset for
cervical dystonia, blepharospasm, laryngeal dystonia and
segmental dystonia in males, while for writer’s cramp and
focal limb dystonia, this trend was reversed.
In summary, as service-based study, our figures may
underestimate the true prevalence of dystonia, but due to
the characteristics of patient ascertainment, it reflects the
point prevalence of patients with dystonia seeking botu-
linum toxin treatment.
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